Some childhood cancer medicines, such as doxorubicin and daunorubicin, and radiotherapy that reached the heart can weaken the heart muscle years later, often with no symptoms at first. International guidance sorts survivors by dose: a heart ultrasound scan every 2 years after higher doses, every 5 years after middle doses, and none after low doses. Carrying on for life is thought reasonable.
The IGHG 2022 recommendations (published 2023) replace the 2015 edition; COG Version 6.0 (October 2023) uses the same dose bands and intervals. Exposure is the cumulative anthracycline dose in doxorubicin equivalents (mitoxantrone included) and the chest radiotherapy dose. Surveillance is recommended after 250 mg/m² or more of anthracycline, 30 Gy or more of chest radiotherapy, or 100 mg/m² or more combined with 15 Gy or more (strong); it is reasonable after 100 to under 250 mg/m² or 15 to under 30 Gy (moderate); it is not recommended below 100 mg/m² or below 15 Gy (strong), which is a change from 2015. The test is left ventricular ejection fraction by 2D or 3D echocardiography, with cardiac MRI where echo windows are inadequate; blood biomarkers are not recommended as the only strategy. For high-risk survivors surveillance is recommended to start no later than 2 years after the end of cardiotoxic treatment and to repeat every 2 years (strong); for moderate-risk survivors it is reasonable to start no later than 2 years after treatment, repeat at 5 years from diagnosis and then every 5 years (moderate); lifelong surveillance is reasonable in both groups (expert opinion). An echocardiogram before pregnancy or in the first trimester is reasonable for every woman treated with anthracyclines or chest radiotherapy. Asymptomatic systolic or diastolic dysfunction is referred to cardiology, and a symptomless ejection fraction under 40 per cent is treated with heart failure medicines as in the general population.
Where the guidelines differ: COG counts radiation to the chest, abdomen, thoracic or whole spine and total body irradiation as dose with potential impact to the heart, adds a baseline ECG and a yearly history and examination, restricts pregnancy cardiology evaluation to higher exposures, and converts anthracyclines with different factors from the IGHG 2025 ratios. SIGN 132 (2013) individualises the interval up to 5 years below 250 mg/m² and 2 to 3 years above it. The ESC 2022 cardio-oncology guideline, for adults who are childhood and adolescent survivors, recommends follow-up according to IGHG and says echocardiography should be considered every 2 years (high risk) and every 5 years (moderate risk), Class IIa, Level B. This page describes guidance so that survivors and families can follow their care; the schedule set by a person's own follow-up team comes first.
Why: The whole schedule depends on these two numbers. COG lists the cumulative anthracycline dose, and the total radiation dose to each field, among the least a treatment summary must hold before its guidelines can be applied.
“Cumulative dose of all anthracycline chemotherapy received (i.e., doxorubicin, daunorubicin, idarubicin, mitoxantrone and epirubicin)”
Why: The drugs differ in how much they affect the heart for each milligram: mitoxantrone counts for about ten times its dose and daunorubicin for less than its dose. The guidelines use slightly different conversion factors (see variants).
“It is reasonable to use a ratio of approximately 10.5 to calculate the mitoxantrone-to-doxorubicin equivalent dose with respect to CTRCD risk (low-quality evidence, moderate recommendation).”
IGHG 2025 · low-quality evidence, moderate recommendation
Why: IGHG says both survivors and their health care providers should be aware of the risk. This is its general recommendation and it names no dose threshold.
“CAYA cancer survivors treated with anthracyclines, chest RT, or both (high-quality evidence), and their health care providers should be aware of the risk of cardiomyopathy (strong recommendation).”
International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 · high-quality evidence, strong recommendation
Why: IGHG makes its strong recommendation at these doses. Its published abstract says heart muscle disease with symptoms is typically preceded by gradual changes without symptoms that treatment can improve.
“Cardiomyopathy surveillance is recommended for CAYA cancer survivors treated with high dose (≥250 mg/m2) anthracyclines (high-quality evidence, strong recommendation)”
International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 · high-quality evidence, strong recommendation
Why: IGHG words this as reasonable, not recommended: a moderate recommendation, which it uses where there is more uncertainty. The scans are also spaced further apart (see the moderate-risk schedule below).
“Cardiomyopathy surveillance is reasonable for CAYA cancer survivors treated with moderate dose (≥100 to <250 mg/m2) anthracyclines (high-quality evidence, moderate recommendation).”
International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 · high-quality evidence, moderate recommendation
Why: IGHG recommends against routine surveillance at these doses. This is a change from the 2015 edition, under which scans every 5 years were reasonable for this group. The documents read do not print the panel's reasons.
“Cardiomyopathy surveillance is not recommended for survivors treated with low dose (<100 mg/m2) anthracyclines (high-quality evidence, strong recommendation).”
International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 · high-quality evidence, strong recommendation
Why: The ejection fraction measures how well the main pumping chamber squeezes, and IGHG names it, measured by ultrasound, as the main test.
“Left-ventricular ejection fraction measured with 2D or 3D echocardiography is recommended as the primary cardiomyopathy surveillance modality for assessment of left-ventricular systolic function in CAYA cancer survivors treated with anthracyclines or chest RT (moderate-quality evidence, strong recommendation).”
International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 · moderate-quality evidence, strong recommendation
Why: IGHG says MRI may be reasonable in that situation. This rests on expert opinion.
“Cardiac magnetic resonance imaging may be reasonable for cardiomyopathy surveillance in at-risk CAYA cancer survivors for whom echocardiography is not technically feasible or optimal (expert opinion, moderate recommendation).”
International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 · expert opinion, moderate recommendation
Why: IGHG recommends against blood tests as the only strategy. It says they may be reasonable together with a scan when heart muscle disease with symptoms is strongly suspected or heart function is borderline.
“Assessment of cardiac blood biomarkers (e.g., natriuretic peptides and troponins) is not recommended as the only strategy for cardiomyopathy surveillance in at-risk CAYA survivors (low- to moderate-quality evidence, strong recommendation).”
International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 · low- to moderate-quality evidence, strong recommendation
Why: IGHG recommends this schedule strongly, on moderate-quality evidence. The 2015 edition said every 5 years, with more frequent scans reasonable.
“Cardiomyopathy surveillance is recommended for high-risk CAYA cancer survivors to begin no later than 2 years after completion of cardiotoxic therapy and continued every 2 years thereafter (moderate-quality evidence, strong recommendation).”
International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 · moderate-quality evidence, strong recommendation
Why: IGHG calls this schedule reasonable, not recommended: a moderate recommendation on low-quality evidence.
“Cardiomyopathy surveillance is reasonable for moderate-risk CAYA survivors to begin no later than 2 years after completion of cardiotoxic therapy, repeated at 5 years after diagnosis, and continue every 5 years thereafter (low-quality evidence, moderate recommendation).”
International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 · low-quality evidence, moderate recommendation
Why: IGHG calls lifelong surveillance reasonable in both the high-risk and the moderate-risk group. It grades this as expert opinion, not as the result of studies.
“Lifelong cardiomyopathy surveillance is reasonable for high-risk CAYA cancer survivors (expert opinion, moderate recommendation).”
International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 · expert opinion, moderate recommendation
Why: COG notes that in younger patients tummy symptoms may be seen more often than breathlessness on exertion or chest pain.
“Abdominal symptoms (nausea, emesis) may be seen more frequently than exertional dyspnea or chest pain in younger patients.”
Why: IGHG recommends this to help avert heart muscle disease with symptoms. COG says these traditional risk factors significantly increase a survivor's risk of cardiomyopathy.
“Screening for and management of modifiable cardiovascular risk factors (hypertension, diabetes, dyslipidemia, obesity, smoking, alcohol intake) is recommended for all CAYA survivors treated with anthracyclines or chest RT to help avert the risk of symptomatic cardiomyopathy (evidence-based guidelines, strong recommendation).”
International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 · evidence-based guidelines, strong recommendation
Why: IGHG calls a heart check at this point reasonable for all women who had these treatments. COG says women whose pumping is reduced before or early in pregnancy, or was in the past, are at highest risk of pregnancy-associated cardiomyopathy.
“Cardiomyopathy surveillance is reasonable before pregnancy or in the first trimester for all female CAYA survivors treated with anthracyclines or chest RT (moderate-quality evidence, moderate recommendation).”
International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 · moderate-quality evidence, moderate recommendation
Why: IGHG calls this reasonable. COG says women with a history of reduced pumping should be monitored periodically during pregnancy, labour and delivery because of an increased risk of heart failure.
“Continuing cardiomyopathy surveillance is reasonable during pregnancy for female CAYA survivors treated with anthracyclines or chest RT who had a history of prior left ventricular systolic dysfunction that has resolved even in the presence of a normal baseline ejection fraction in the first trimester (moderate-quality evidence, moderate recommendation).”
International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 · moderate-quality evidence, moderate recommendation
Why: IGHG recommends a cardiology consultation for these findings even without symptoms. The recommendation is strong and rests on expert opinion.
“Cardiology consultation is recommended for CAYA survivors with asymptomatic left-ventricular systolic or diastolic dysfunction** following treatment with anthracyclines or chest RT (expert opinion, strong recommendations).”
International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 · expert opinion, strong recommendations
Why: IGHG applies the guidelines written for the general population, and grades the evidence as evidence from the general population.
“Treatment with heart failure medications (e.g. ACE inhibitors, ARBs, beta-blockers) is recommended in CAYA cancer survivors with asymptomatic left-ventricular ejection fraction <40%, according to guidelines from the general population (low- to high-quality evidence in the general population, strong recommendation).”
International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 · low- to high-quality evidence in the general population, strong recommendation
Why: COG says exercise is generally safe and encouraged when the heart's pumping is normal. COG and IGHG both send survivors with symptomless cardiomyopathy to a cardiologist to define limits, and suggest the same be considered for high-risk survivors planning intensive exercise.
“Exercise is generally safe and encouraged for patients with normal LV systolic function”
Children's Oncology Group 2023 · SCORE = 1
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
The IGHG 2022 recommendations (Lancet Oncology 2023) are the most recent harmonised international guideline, and COG Version 6.0 uses the same dose bands and intervals. The two agree on the core: sort survivors by cumulative doxorubicin-equivalent anthracycline dose and heart radiation dose; echocardiography every 2 years for high risk and every 5 years for moderate risk; attention to blood pressure, diabetes, lipids and weight for all. IGHG grades the high-risk schedule as a strong recommendation on moderate-quality evidence and the moderate-risk schedule as a moderate recommendation on low-quality evidence; lifelong continuation is expert opinion. COG states that no randomised trials of screening exist in this population and scores its sections by expert consensus. The sources read differ in five places, and none is settled by a trial. (1) Low risk: IGHG 2022 and COG 6.0 recommend no echocardiographic screening below 100 mg/m² and below 15 Gy; IGHG 2015 and SIGN 132 (2013) scanned this group at up to 5-year intervals. (2) Radiation dose: IGHG states a chest radiotherapy dose (15 and 30 Gy); COG counts chest, abdomen, thoracic or whole spine and total body irradiation; ESC 2022 sorts adult survivors by mean heart dose. (3) Dose conversion: IGHG 2025 gives daunorubicin about 0.6 and mitoxantrone about 10.5 and makes no recommendation for a ratio other than 1 for epirubicin or any ratio for idarubicin; COG 6.0 uses daunorubicin 0.5, epirubicin 0.67, idarubicin 5 and mitoxantrone 10. (4) Pregnancy: IGHG finds an echocardiogram reasonable for all women treated with anthracyclines or chest radiotherapy; COG indicates cardiology evaluation after 250 mg/m² or more, 30 Gy or more, or any anthracycline with 15 Gy or more; SIGN says no repeat scan is needed if one was normal in the previous three years. (5) Extras: COG adds a baseline ECG with QTc and a yearly history and examination; IGHG makes no ECG recommendation in the document read. ESC 2022, written for adults who are childhood and adolescent cancer survivors, recommends follow-up according to IGHG and grades the two echocardiography intervals Class IIa, Level B (should be considered).
International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 · Children's Oncology Group 2023 · IGHG 2025 · Scottish Intercollegiate Guidelines Network 2013 · IGHG 2022 · European Society of Cardiology, European Heart Journal 2022
Where it differs: Uses the same dose bands and the same 2-year and 5-year intervals as IGHG 2022, set out as a table of anthracycline dose against radiation dose, and adds four things. The radiation dose is "Based on radiation dose with potential impact to heart (radiation to chest, abdomen, spine [thoracic, whole], TBI)." An ECG is added: "EKG (include evaluation of QTc interval) Baseline at entry into long-term follow-up, repeat as clinically indicated". History and examination with blood pressure are yearly (in the radiation section, where the dose was 15 Gy or more, which is also where that section asks for the ECG). For pregnancy, additional cardiology evaluation is indicated after 250 mg/m² or more of anthracycline, 30 Gy or more of chest radiation, or any dose of anthracycline with 15 Gy or more, and "Evaluation should include a baseline echo (pre- or early-pregnancy)." Doses are converted with doxorubicin 1.0, daunorubicin 0.5, epirubicin 0.67, idarubicin 5.0 and mitoxantrone 10.0. It also says a cardiology consultation 5 to 10 years after radiation may be reasonable to evaluate coronary artery disease risk after 30 Gy or more of chest radiation alone or 15 Gy or more with an anthracycline.
Evidence: Expert consensus scored 1 on COG's scale (high-level evidence for the link between exposure and late effect, uniform consensus on the screening). Version 6.0 states the change from Version 5.0: "Echocardiogram screening is not recommended for individuals with both <15Gy radiation dose (with potential impact to heart) and a cumulative doxorubicin equivalent anthracycline dose <100 mg/m2", and that the mitoxantrone conversion changed from 4 to 10. COG's preface says there are no randomised trials on which to base screening recommendations in this population.
Where it differs: Recommends long-term echocardiographic monitoring for everyone who had anthracyclines or radiation to a field that includes the heart, measuring fractional shortening and ejection fraction, with "a maximum interval of five years for those at low risk who received cumulative anthracycline doses less than 250 mg/m2" and screening every two to three years above 250 mg/m² or with heart radiotherapy. On pregnancy: "Women who are pregnant or planning a pregnancy do not require repeat echocardiograph if they have had a normal test result in the previous three years."
Evidence: The monitoring recommendation is grade D on SIGN's scale and the interval statements are good practice points. The guideline dates from March 2013, before either IGHG edition, and SIGN's own page says some recommendations may be out of date. It has no group that is not scanned.
Where it differs: Scanned all three risk groups every 5 years, with more frequent scans reasonable for high risk and "may be reasonable" for moderate and low risk; set the radiotherapy bands at 15 to under 35 Gy and 35 Gy or more; and for low-dose anthracyclines (under 100 mg/m²) said surveillance may be reasonable. Radionuclide angiography was an alternative to echocardiography; the 2022 edition names cardiac MRI only.
Evidence: Read from IGHG's own side-by-side document of the 2015 and 2022 wording. A survivor given a schedule before 2023, or by a clinic still using the first edition, may be on these intervals.
Where it differs: A simulation model compared echocardiograms every 1, 2, 5 and 10 years with no screening in each risk group of the 2015 edition, when high-risk survivors were scanned every 5 years and low-risk survivors were still scanned. It favoured a 2-year interval for high-risk survivors and no screening for low-risk survivors, which is where the 2022 edition went.
Evidence: Ehrhardt 2020 (full text; model built on the Childhood Cancer Survivor Study and St Jude Lifetime Cohort): modelled lifetime risk of heart failure without screening was 36.7 per cent in the high-risk group, 24.7 per cent in the moderate-risk group and 16.9 per cent in the low-risk group as then defined, and routine screening reduced that risk by 4 to 11 per cent depending on frequency. "Screening every 2, 5, and 10 years was cost-effective for high-risk survivors, and every 5 and 10 years for moderate-risk survivors." In high-risk survivors the 2-year interval gave the greatest gain and was the strategy most often preferred in the simulations; the authors called the best strategy for moderate-risk survivors uncertain. For low-risk survivors every strategy cost more than 175,000 dollars for each quality-adjusted life-year gained, against a threshold of 100,000, so none counted as cost-effective. These are model estimates, not trial results, costed on United States Medicare rates, and the risk groups were those of the 2015 edition (35 Gy, not 30 Gy, as the upper radiation band).
Where it differs: Some clinics scan less often after dexrazoxane, a medicine given with anthracyclines to protect the heart, or adjust for genetic test results.
Evidence: IGHG 2022 found the evidence too thin to support either: "No recommendation can be formulated to change cardiomyopathy surveillance in CAYA cancer survivors who received dexrazoxane cardioprotection with anthracycline administration (low-quality evidence)." The same wording is used for genetic variants that raise or lower risk.
International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022
Where it differs: Written by cardiologists for adult survivors. It recommends follow-up according to IGHG and words the intervals more cautiously than IGHG does for the high-risk group: "A CV review should be considered every 5 years for moderate-risk childhood and adolescent adult CS and every 2 years for high-risk childhood and adolescent adult CS." It asks for screening for modifiable cardiovascular risk factors every year, and recommends a cardiovascular assessment before pregnancy or in the first trimester for female survivors, which its footnote spells out as blood pressure, lipids, fasting glucose, HbA1c, an ECG and an echocardiogram. Its risk table sorts survivors by mean heart dose, not chest dose, and adds a very-high-risk category; the table does not read reliably as text, so its numbers are not given here.
Evidence: Recommendation Table 40: education of survivors and their healthcare providers is Class I, Level B; annual screening for modifiable risk factors is Class I, Level C; cardiovascular assessment before or early in pregnancy is Class I, Level C; echocardiography every 2 years in high-risk and every 5 years in moderate-risk survivors is Class IIa, Level B in each case. The text adds that lifelong surveillance for high-risk survivors is recommended. The guideline dates from 2022 and cites the first IGHG edition; in the section read it does not say whether low-risk survivors should be scanned.
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Surveillance after 30 Gy or more of chest radiotherapy “Cardiomyopathy surveillance is recommended for CAYA cancer survivors treated with high dose (≥30 Gy) chest RT (high-quality evidence, strong recommendation).” | high-quality evidence, strong recommendation | International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 |
| Surveillance after 15 to under 30 Gy of chest radiotherapy “Cardiomyopathy surveillance is reasonable for CAYA cancer survivors treated with moderate dose (≥15 to <30 Gy) chest RT (high-quality evidence, moderate recommendation).” | high-quality evidence, moderate recommendation | International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 |
| No surveillance after under 15 Gy of conventionally fractionated chest radiotherapy “Cardiomyopathy surveillance is not recommended for CAYA cancer survivors treated with low dose (<15 Gy) chest RT with conventional fractionation (high-quality evidence, strong recommendation).” | high-quality evidence, strong recommendation | International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 |
| Surveillance after 100 mg/m² or more of anthracycline combined with 15 Gy or more of chest radiotherapy “Cardiomyopathy surveillance is recommended for CAYA cancer survivors treated with moderate to high dose anthracyclines (≥100 mg/m2) and moderate to high dose chest RT (≥15 Gy) (high-quality evidence, strong recommendation).” | high-quality evidence, strong recommendation | International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 |
| Lifelong surveillance in the moderate-risk group “Lifelong cardiomyopathy surveillance is reasonable for moderate-risk CAYA cancer survivors (expert opinion, moderate recommendation).” | expert opinion, moderate recommendation | International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 |
| Natriuretic peptides alongside imaging when symptoms are suspected or function is borderline “Assessment of cardiac blood biomarkers (e.g., natriuretic peptides) in conjunction with imaging studies may be reasonable in instances where symptomatic cardiomyopathy is strongly suspected or in CAYA cancer survivors who have borderline cardiac function during primary surveillance (expert opinion, moderate recommendation).” | expert opinion, moderate recommendation | International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 |
| No recommendation on heart failure medicines for symptomless borderline heart function (the source prints "between 40% and the upper limit of normal") “No recommendations can be formulated about treatment with heart failure medications in CAYA cancer survivors with asymptomatic borderline cardiac function (left-ventricular ejection fraction between 40% and the upper limit of normal) (no studies in CAYA cancer survivors, no evidence in the general population).” | no studies in CAYA cancer survivors, no evidence in the general population | International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 |
| Cardiology advice on exercise limits for survivors with asymptomatic cardiomyopathy “Cardiology consultation is recommended for CAYA survivors with asymptomatic cardiomyopathy to define limits and precautions for exercise (expert opinion, strong recommendation).” | expert opinion, strong recommendation | International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 |
| Cardiology advice for high-risk survivors planning high-intensity exercise “Cardiology consultation is reasonable for high-risk CAYA survivors who plan to participate in high intensity exercise to define limits and precautions for physical activity (expert opinion, moderate recommendation).” | expert opinion, moderate recommendation | International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) 2022 |
| Daunorubicin counts for about 0.6 of its dose in doxorubicin equivalents “It is reasonable to use a ratio of approximately 0.6 to calculate the daunorubicin-to-doxorubicin equivalent dose with respect to CTRCD risk (low-quality evidence, moderate recommendation).” | low-quality evidence, moderate recommendation | IGHG 2025 |
| No ratio other than 1 can be recommended for epirubicin “No recommendation can be made to use a ratio other than 1 when estimating CTRCD risk of epirubicin compared with doxorubicin (low-quality evidence).‡” | low-quality evidence | IGHG 2025 |
| No ratio can be recommended for idarubicin “No recommendation can be made for an idarubicin-to-doxorubicin equivalence ratio with respect to CTRCD risk, as no eligible studies were identified.” | no eligible studies | IGHG 2025 |
| COG: counsel on blood pressure, body mass index, lipids and glucose “Counsel regarding the importance of maintaining blood pressure, BMI, lipids, and glucose levels within goal ranges per general population guidelines.” | SCORE = 1 | Children's Oncology Group 2023 |
| COG: cardiac MRI when echocardiogram images are suboptimal “Cardiac MRI as an adjunct imaging modality when echo images are suboptimal.” | SCORE = 1 | Children's Oncology Group 2023 |
| ESC: echocardiography every 5 years (moderate risk) and every 2 years (high risk) in adult survivors “A CV review should be considered every 5 years for moderate-risk childhood and adolescent adult CS and every 2 years for high-risk childhood and adolescent adult CS.” | IIa, B | European Society of Cardiology, European Heart Journal 2022 |
| SIGN: long-term echocardiographic monitoring after anthracyclines or heart radiation “Survivors of childhood cancer who have had anthracyclines or radiation to a field that includes the heart should have long term monitoring for cardiac dysfunction using echocardiography to determine fractional shortening and ejection fraction.” | D | Scottish Intercollegiate Guidelines Network 2013 |
Shares Heart risk assessment and monitoring before, during and after heart-toxic cancer treatment, Dexrazoxane, Anthracyclines (doxorubicin, epirubicin), Cardiotoxicity (LVEF decline, cardiomyopathy).
Shares Dexrazoxane, The heart after anthracyclines and chest radiotherapy in childhood, Epirubicin, Cardio-oncology.
Shares International Guideline Harmonization Group for late effects of childhood cancer, The heart after anthracyclines and chest radiotherapy in childhood, The Children's Oncology Group Long-Term Follow-Up Guidelines, Late effects and survivorship toxicity.
Shares International Guideline Harmonization Group for late effects of childhood cancer, The Children's Oncology Group Long-Term Follow-Up Guidelines, Late effects and survivorship toxicity, Childhood cancers (all types).
Shares Heart risk assessment and monitoring before, during and after heart-toxic cancer treatment, Cardio-oncology, Survivorship and late effects are neglected.
Shares Idarubicin, Dexrazoxane, Mitoxantrone, Daunorubicin.
Shares Dexrazoxane, Anthracyclines (doxorubicin, epirubicin), Cardiotoxicity (LVEF decline, cardiomyopathy), Cardio-oncology.
Shares International Guideline Harmonization Group for late effects of childhood cancer, The Children's Oncology Group Long-Term Follow-Up Guidelines, Late effects and survivorship toxicity, Childhood cancers (all types).